APELLIS PHARMACEUTICALS INC - NOTE 3.500% 9/1

Q2 2022 13F Holders as of 30 Jun 2022

Type / Class
Debt / NOTE 3.500% 9/1
Number of holders
13
Total 13F principal, excl. options
138,949,000
Principal change
-60,871,000
Total reported value, excl. options
$205,684,098
Value change
-$92,889,077
Number of buys
2
Number of sells
-10
Price
$1.49

Significant Holders of APELLIS PHARMACEUTICALS INC - NOTE 3.500% 9/1 as of Q2 2022

18 filings reported holding 03753UAB2 - APELLIS PHARMACEUTICALS INC - NOTE 3.500% 9/1 as of Q2 2022.
APELLIS PHARMACEUTICALS INC - NOTE 3.500% 9/1 has 13 institutional bondholders that have filed 13F forms with the Securities Exchange Commission (SEC). These institutions hold a total of $138,949,000 of principal .
Largest 10 bondholders include DEERFIELD MANAGEMENT COMPANY, L.P. (SERIES C) ($51,885,000 of principal), WOLVERINE ASSET MANAGEMENT LLC ($43,874,000 of principal), DeepCurrents Investment Group LLC ($17,550,000 of principal), WELLS FARGO & COMPANY/MN ($8,325,000 of principal), LAZARD ASSET MANAGEMENT LLC ($7,566,000 of principal), WELLINGTON MANAGEMENT GROUP LLP ($5,788,000 of principal), SILVERBACK ASSET MANAGEMENT LLC ($2,000,000 of principal), PALISADE CAPITAL MANAGEMENT LLC/NJ ($1,017,000 of principal), CITIGROUP INC ($393,000 of principal), and KORNITZER CAPITAL MANAGEMENT INC /KS ($300,000 of principal).
This table shows the top 13 institutional bondholders of the company debt. This data is sourced directly from the SEC via 13F filings.
Investor Option Weight % Change % Value $ * Price $ Principal Share Change Activity Report Period
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.